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mechanisms relevant to
neurodegeneration.
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Axon injury leads to rapid depletion of NAD-biosyn-
thetic enzyme NMNAT2 and high levels of its sub-
strate, NMN. We proposed a key role for NMN in
Wallerian degeneration but downstream events
and their relationship to other mediators remain un-
clear. Here, we show, in vitro and in vivo, that axot-
omy leads to a late increase in intra-axonal Ca2+,
abolished by pharmacological or genetic reduction
of NMN levels. NMN requires the pro-degenerative
protein SARM1 to stimulate Ca2+ influx and axon
degeneration. While inhibition of NMN synthesis
and SARM1 deletion block Ca2+ rise and preserve
axonal integrity, they fail to prevent early mitochon-
drial dynamic changes. Furthermore, depolarizing
mitochondria does not alter the rate of Wallerian
degeneration. These data reveal that NMN and
SARM1 act in a common pathway culminating in
intra-axonal Ca2+ increase and fragmentation and
dissociate mitochondrial dysfunctions from this
pathway, elucidatingwhich stepsmay bemost effec-
tive as targets for therapy.
INTRODUCTION
Axon degeneration is an early event contributing to symptoms in
a range of age-related neurodegenerative disorders, including
Parkinson’s disease, Huntington’s disease, Alzheimer’s disease,
motor neuron disease, and multiple sclerosis. Axonal damage
also underpins peripheral neuropathies and is a limiting side ef-
fect of cancer chemotherapeutic agents (Conforti et al., 2014).
Maintaining axon structure and function is therefore a promising
therapeutic goal for these disorders.
Two genetic modifications can delay by 10-fold axon degen-
eration after an acute injury, a process known as Wallerian
degeneration (Waller, 1850), highlighting the existence of a regu-
lated and active axon death pathway. First, expression of the
neuroprotective factor Wallerian Degeneration Slow (WLDs), a
chimeric protein which fuses the nuclear isoform of the nicotin-
amide adenine dinucleotide (NAD)-biosynthetic enzyme nicotin-Cell Repamide mononucleotide adenylyltransferase 1 (NMNAT1) with an
N-terminal sequence that relocates this enzyme from the nu-
cleus to the cytoplasm and axons (Avery et al., 2009; Conforti
et al., 2000, 2009; Mack et al., 2001). WLDs is effective in mice,
rats, Drosophila, zebrafish and in primary human neuronal cul-
ture (Adalbert et al., 2005; Kitay et al., 2013; Lunn et al., 1989;
MacDonald et al., 2006; Martin et al., 2010), indicating strong
evolutionary conservation of the axon degeneration pathway
with which it interferes. WLDs also ameliorates axon pathology
and symptoms in some disease models (Conforti et al., 2014),
highlighting shared mechanisms and translational potential.
Remarkably, loss of the Toll-like receptor adaptor protein Sterile
alpha and TIR motif containing 1 (SARM1) has the same robust
protective efficacy of WLDs. Similar to WLDs, the protective ef-
fect of SARM1 deletion is evolutionarily conserved in mice and
Drosophila (Osterloh et al., 2012).
It has been proposed that WLDs delays axon degeneration
by substituting for the endogenous but short-lived axonal
NMNAT isoform NMNAT2, whose enzyme activity is required
for axon growth and maintenance. NMNAT2 is synthesized in
the cell bodies, actively transported down the axons, and rapidly
degraded after injury or block of axonal transport. WLDs, which
retains the same enzymatic activity than NMNAT2 but is much
more stable, prolongs axon integrity (Gilley et al., 2013; Gilley
and Coleman, 2010; Milde et al., 2013).
Our previous data support amodel in whichWLDs/NMNAT ac-
tivity maintains axon integrity by preventing the accumulation of
its substrate, the pro-degenerative NAD precursor nicotinamide
mononucleotide (NMN). NMN increases after injury likely as a
consequence of NMNAT2 depletion and its pharmacological or
genetic inhibition strongly delaysWallerian degeneration (Di Ste-
fano et al., 2014). The robustness of axon protection phenotype
conferred by SARM1 deletion resembles that obtained by scav-
enging of NMN. Crucially, SARM1 depletion blocks NMNAT2
loss-induced axon degeneration but does not reduce NMN, indi-
cating that SARM1 influences the same pathway of axon death
downstream of NMN, or a convergent pathway, while other
weaker modulators may join onto this pathway (Conforti et al.,
2014; Gilley et al., 2015; Yang et al., 2015).
NMN increases early after injury (Di Stefano et al., 2014),
leaving ample scope for downstream events, which could
include an effect on intra-axonal Ca2+. A key role for Ca2+
in the late steps of degeneration, likely acting by activatingorts 13, 2539–2552, December 22, 2015 ª2015 The Authors 2539
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Ca2+-dependent proteases, has long been recognized (George
et al., 1995; Wang et al., 2012). Ca2+ could reach the axons
from the extracellular environment or originate from intra-axonal
organelles (Barrientos et al., 2011; Villegas et al., 2014). Recent
studies suggest instead that Ca2+ rise may occur early after
injury (Avery et al., 2012), possibly acting upstream of SARM1
(Summers et al., 2014).
Mitochondria have been reported as central executors in Wal-
lerian degeneration through mitochondrial permeability transi-
tion pore (mPTP) opening, which could result from a crosstalk
with the endoplasmic reticulum (ER) (Barrientos et al., 2011;
Villegas et al., 2014). Augmented mitochondrial motility in
WLDs could increase Ca2+ buffering capability and contribute
to protection (Avery et al., 2012). However, Wallerian degenera-
tion is only modestly delayed in axons devoid of mitochondria in
some models and mitochondria are dispensable for WLDs pro-
tection (Kitay et al., 2013); therefore, the role of mitochondria in
Wallerian degeneration and the WLDs mechanism as well as
the relationships among NMN increase, SARM1, Ca2+, andmito-
chondrial dynamics remain unresolved.
Here we report that intra-axonal Ca2+ elevation after axotomy
lies downstream of NMN and immediately precedes axon frag-
mentation. We found that SARM1 is required for NMN to initiate
axon degeneration and that Ca2+ rise is a common downstream
step. Both NMN rise inhibition and SARM1 deletion fail to pre-
vent changes in mitochondrial dynamics occurring after axot-
omy, despite delaying degeneration. We also found that the
rate of Wallerian degeneration is not affected by mitochondrial
depolarization. By clarifying the temporal relationship between
NMN rise, SARM1, Ca2+, and mitochondrial dynamics, our re-
sults identify critical steps ofWallerian degeneration where phar-
macological intervention could be most successful.
RESULTS
Pharmacological and Genetic Data Indicate that NMN
Induces a Rise in Intra-axonal Ca2+ Rapidly Followed by
Axon Fragmentation
To address events downstream of NAD-precursor NMN (Fig-
ure S1A), which we proposed to induce axon degeneration after
injury (Di Stefano et al., 2014), we first testedwhether NMNaccu-
mulation evokes changes in intra-axonal Ca2+ concentration.Figure 1. NMN Induces a Rise in Intra-axonal Ca2+ Rapidly Followed b
(A) Plasmids encoding for the Ca2+ indicator GCaMP5 and for the axonal marker D
microinjection and left untreated or treated as shown with FK866 and NMN, add
5 min up to 260 min. Scale bar represents 50 mm.
(B) Quantification of Ca2+ peak intensities (see Experimental Procedures). All mea
confers protection after axotomy, completely abolished injury-induced Ca2+ ris
protection. Mean ± SEM; n = 6, two fields in three independent experiments; on
(C) Representative traces showing Ca2+ responses in axon fragments distal to th
that Ca2+ rise shortly preceded axonal fragmentation in both the untreated and
treated sample.
(D) Fluorescent images of wild-type SCG axons co-injected with plasmids enco
indicated time points after transection. Scale bar represents 50 mm.
(E) Quantification of Ca2+ peak intensities. All measurements were normalized to
axons. Mean ± SEM; n = 6, two fields in three independent experiments; one-wa
(F) Representative traces showing no Ca2+ increase in NMN deamidase distal ax
See also Figures S1 and S2.
Cell RepThis is important since WLDs, which blocks NMN accumulation,
has been suggested to protect degenerating axons by inhibiting
Ca2+ increase or enhancing its buffering (Adalbert et al., 2012;
Avery et al., 2012). To analyze the temporal correlation between
Ca2+ rise and axonal fragmentation, we microinjected superior
cervical ganglia (SCG) neurons with plasmids encoding the
Ca2+ indicator GCaMP5 and the fluorescent marker DsRed2.
One day after microinjection, the axons were separated from
the cell bodies and changes in GCaMP5 fluorescence signal in
distal stumps were measured and normalized to their corre-
sponding uncut controls (Figure 1; Figures S1B and S1C).
Consistent with previous studies (Adalbert et al., 2012), we found
a marked increase in Ca2+ levels in distal injured axons starting
2–3 hr after axotomy (Figures 1A and 1B; Movie S1). This Ca2+
rise just preceded the appearance of morphological damage
and axon integrity was lost 10–25 min after Ca2+ started to in-
crease (Figures 1A and 1C). To test whether this Ca2+ rise was
induced by NMN accumulation, we treated axons with FK866,
a potent and specific inhibitor of NMN-synthesizing enzyme
NAMPT (Figure S1A). FK866 completely abolished the Ca2+
rise and, consistent with our previous report (Di Stefano et al.,
2014), preserved axonal integrity for the entire duration of the
experiment (Figures 1A–1C; Movie S1). Co-administration of
NMN fully reverted the effects of FK866, restoring Ca2+ rise
and axonal fragmentation (Figures 1A–1C; Movie S1).
We previously showed that scavenging NMN by expressing
the bacterial enzyme NMN deamidase (Figure S1A; Galeazzi
et al., 2011) remarkably delays axon degeneration after injury
(Di Stefano et al., 2014). We then asked whether this genetic
intervention to reduce NMN could also block intra-axonal Ca2+
rise and found that expressing NMN deamidase completely
abolished this increase and preserved axonal integrity for the
entire duration of the experiment (Figures 1D–1F; Movie S1).
Thus, NMN increase after injury evokes a late intra-axonal
Ca2+ rise, which can be blocked by NAMPT inhibitor FK866 or
by genetically scavenging NMN.
NMN Requires SARM1 to Induce Degeneration and
Intra-axonal Ca2+ Increase
Because injured Sarm1/ nerves have high NMN levels but
do not degenerate (Gilley et al., 2015), it is likely that SARM1 is
required for NMN to induce axon death.We tested this possibilityy Axon Fragmentation
sRed2weremicroinjected into wild-type SCG nuclei; axonswere cut 1 day after
ed immediately after cut. Time-lapse fluorescent images were acquired every
surements were normalized to uncut controls. FK866, which blocks NMN and
e; NMN addition re-established Ca2+ increase and reverted FK866-mediated
e-way ANOVA followed by Bonferroni post hoc test; ***p < 0.001.
e injury site over time in correlation with the percentage of healthy axons. Note
FK866+NMN-treated samples. No Ca2+ increase was detected in the FK866-
ding GCaMP5, DsRed2, and either NMN deamidase or Empty vector, at the
uncut controls. No Ca2+ increase was detected in NMN deamidase expressing
y ANOVA followed by Bonferroni post hoc test; ***p < 0.001.
on fragments in correlation with the percentage of healthy axons.
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Figure 2. NMN Requires SARM1 to Induce Axon Degeneration and Ca2+ Rise
(A) Bright field images of Sarm1/ SCG axons left untreated or treated with 1 mM NMN as shown, at the indicated time points after cut. Scale bar
represents 50 mm.
(B) Degeneration index was calculated from three fields per sample in three independent experiments. Mean ± SEM; n = 9; one-way ANOVA followed by
Bonferroni post hoc test.
(C) Fluorescent images of Sarm1/ SCG transected axons expressing GCaMP5 and DsRed2, untreated or treated with 1mMNMN. Scale bar represents 50 mm.
(D) Quantification of Ca2+ peak intensities. All measurements were normalized to uncut controls. Mean ±SEM; n = 6, two fields in three independent experiments;
one-way ANOVA followed by Bonferroni post hoc test, p = 0.3698.
(E) Representative traces showing no increase in Ca2+ responses in distal Sarm1/ axons cut and left untreated or cut and treated with 1 mMNMN as shown, in
correlation with the percentage of healthy axons.
See also Figures S1 and S2.by adding NMN to transected Sarm1/ axons and found that
they remained intact for at least 4 days, even in the presence
of high concentrations of exogenous NMN (Figures 2A and
2B), which we even tested up to 5 mM (data not shown). In
contrast, FK866-protected wild-type neurites degenerate within
3 hr when exposed to concentrations of NMN 200-fold lower (Di
Stefano et al., 2014). Thus, NMN requires SARM1 to induce axon
degeneration.
We then asked whether SARM1 is also required for the
increase in intra-axonal Ca2+ after cut. This is important in
view of a recent report that SARM1 acts downstream of2542 Cell Reports 13, 2539–2552, December 22, 2015 ª2015 The AuCa2+ (Summers et al., 2014). However, in our experimental
conditions we did not find any increase after axotomy in
Ca2+ signals in the distal stumps of Sarm1/ axons (Fig-
ures 2C and 2D; Movie S2), which remained similar to the
uninjured neurites (Figures S1D and S1E). In parallel, axonal
integrity was preserved for the entire duration of the experi-
ment (Figures 2C and 2E). NMN administration failed to
induce Ca2+ rise in Sarm1/ injured axons (Figures 2C–2E;
Movie S2).
Thus, SARM1 is required for NMN to induceWallerian degener-
ation and Ca2+ increase represents a common downstream step.thors
Figure 3. NMN-Synthesis Inhibitor FK866 Delays Injury-Induced Intra-axonal Ca2+ Increase In Vivo
(A) Schematic representation of larval zebrafish tail indicating the position of the sensory (Rohon-Beard) axons and showing the site of axotomy (yellow arrow).
(B) Time-lapse fluorescent images of axons expressing DsRed and GCaMP-HS, treated with vehicle or 400 mMFK866 as shown and then transected. The yellow
arrow indicates the cut site. White arrows in (f) and (g) show a clear Ca2+ increase immediately preceding the appearance of morphological damage. The
enlargement represents the boxed area in panel (c). Scale bar represents 50 mm.
(C) Time to beginning of fragmentation following laser axotomy; each point represents one fish; horizontal bar denotes average degeneration time (Vehicle n = 7,
FK866 n = 8; Student’s t test; **p < 0.01).
(D) Quantification of Ca2+ peak intensities. F0 (first time point imaged) was set to 1 (mean ± SEM; n = 7–8; Students’s t test; **p < 0.01).
(E) Representative traces showing Ca2+ responses distal to the injury site over time in correlation with the percentage of healthy axonal branches.A Rapid Ca2+ Increase near the Injury Site Is Not
Abolished in Sarm1/, NMN Deamidase, or FK866-
Treated Axons
An increase in intra-axonal Ca2+ in proximity to the cut rapidly
follows the transection injury, and it is most likely due to an influx
from the cut site (Adalbert et al., 2012). This immediate and local-
ized Ca2+ rise leads to rapid degeneration of a short axonalCell Repsegment adjacent to the site of cut, an event known as acute
axon degeneration (Kerschensteiner et al., 2005). We recorded
an early rise in Ca2+ levels in Sarm1/ axons near the cut site,
followed by degeneration of short axonal segments. This was
also observed in wild-type controls untreated or treated with
FK866 or with FK866+NMN and in NMN deamidase-expressing
axons (Figure S2) and it is consistent with direct influx of Ca2+orts 13, 2539–2552, December 22, 2015 ª2015 The Authors 2543
from the injury site. This suggests that Sarm1/ and NMN
deamidase axons, as well as axons treated with FK866, retain
the capability to degenerate in response to Ca2+, but that this
early, proximal Ca2+ rise is distinct from the delayed increase
in the distal stump that occurs just before frank fragmentation
(Figure 1).
Inhibiting NMN Synthesis with FK866 Delays Injury-
Induced Intra-axonal Ca2+ Increase In Vivo
To assess the relationship between NMN and intra-axonal
Ca2+ in vivo, we used zebrafish larvae 48–54 hours post-
fertilization (hpf), transiently expressing DsRed along with the
calcium sensor GCaMP-HS in trigeminal and Rohon–Beard so-
matosensory neurons. These were treated with FK866 for 6
hours prior to two-photon laser axotomy (Figures 3A and 3B).
As we previously reported, FK866 strongly delays axon frag-
mentation in this model organism (Figures 3Bm–3Bo and 3C;
(Di Stefano et al., 2014)). Consistent with our in vitro observa-
tions, we detected a marked Ca2+ increase within axons distal
to the injury site (Figures 3Be–3Bh and 3D). The first signs of
axon damage appeared as soon as 4 min after Ca2+ rise (Fig-
ures 3Ba–3Bd and 3E; Movie S3). FK866 remarkably delayed
this increase in intra-axonal Ca2+ (Figures 3Bp, 3Br, 3D, and
3E; Movie S4) and the subsequent axon fragmentation (Figures
3Bm–3Bo, 3C, and 3E).
Thus, NMN synthesis inhibitor FK866 blocks the increase in
Ca2+ that immediately precedes axonal fragmentation in vivo in
a vertebrate model organism.
The Extracellular Environment Is the Main Source of
NMN-Induced Intra-axonal Ca2+ Rise
Because both extracellular influx of Ca2+ and its release from
intracellular stores have been implicated in Wallerian degener-
ation (Wang et al., 2012), we asked what is the primary source
of the Ca2+ rise induced by NMN. SCG explant axons were
cut and immediately treated with FK866. In order to exclude
intracellular conversion of NMN to NAD mediated by any resid-
ual axonal NMNAT2, we added NMN to FK866-protected neu-
rites 12 hr after cutting (Figure 4A), a time when little or no
NMNAT2 remains (Gilley and Coleman, 2010). In these condi-
tions, NMN induces complete degeneration of FK866-pro-
tected axons within 3 hr from its addition (Figures 4Be–4Bl
and 4C; (Di Stefano et al., 2014)). We used EGTA to chelate
extracellular Ca2+ and saw a remarkable delay of axon degen-
eration after NMN addition (Figures 4Bm–4Bp and 4C). Similar
results were obtained using L-type Ca2+ channels blockers
verapamil (Figures 4Bq–4Bt and 4C) and nifedipine (Figures
S3A (i–l) and S3B). In addition, also KB-R7943, an inhibitor of
the reverse Na+/Ca2+ exchanger, significantly delayed NMN-
induced degeneration, although its effect was weaker (Figures
4Bu–4Bx and 4C). EGTA was protective also in dorsal root gan-
glion (DRG) cultures (Figure S4).
A release of Ca2+ from axonal ER, leading to mPTP opening
and release of intra-mitochondrial Ca2+ has been observed
in the execution phase of Wallerian degeneration (Villegas
et al., 2014). Therefore, we tested whether this sequence of
events is induced by NMN. We observed that ryanodine re-
ceptor antagonist ryanodine significantly delayed NMN-2544 Cell Reports 13, 2539–2552, December 22, 2015 ª2015 The Auinduced degeneration, although its effect was weaker than
that obtained with EGTA and the other Ca2+-channel blockers
used (Figures S3A (m–p) and S3B; Figures 4B and 4C). We
also found that cyclosporine A and ruthenium red, which block
mPTP opening (Barrientos et al., 2011), more modestly influ-
ence the rate of NMN-induced axon degeneration in our model
(Figures S3C (i–p) and S3D). These results indicate that the
main source of intra-axonal Ca2+ stimulated by NMN is the
extracellular environment, with a weaker contribution from
intracellular organelles.
To investigate the temporal relationship between Ca2+ influx
and its internal release and to detect any Ca2+ increase in
areas surrounding mitochondria, Ca2+ buffering organelles
which have been proposed to release Ca2+ during Wallerian
degeneration (Avery et al., 2012; Barrientos et al., 2011; Ville-
gas et al., 2014), we microinjected SCG neurons with GCaMP5
and the mitochondrial marker TagRFP-mito. We then cut
the axons and immediately added FK866 and NMN. As ex-
pected, NMN administration induced a diffuse intra-axonal
Ca2+ increase in FK866-treated axons, rapidly followed by
the formation of Ca2+-rich axonal swellings which started to
appear as early as 10 min after Ca2+ rise (Figures 4Da, 4Db,
4Dd, and 4E; Figure S5A; see also Figure 1). Eighty percent
of these swellings contained mitochondria (Figures 4Db and
4Dd)). The relative Ca2+ fluorescence intensity inside axonal
swellings was significantly higher compared to the signals
measured inside adjacent axonal segments (Figures S5A and
S5B), suggesting an accumulation of Ca2+ at the sites of
morphological damage. EGTA addition drastically reduced
NMN-induced Ca2+ rise (Figures 4De and 4E) and blocked
axon degeneration (Figures 4Bm–4Bp and 4C). However, we
still observed a weak increase in Ca2+ levels confined in
some axonal areas where mitochondria were present (Figures
4De and 4E). This localized Ca2+ rise was considerably weaker
than that observed following extracellular Ca2+ influx (Fig-
ure 4E); small swellings also appeared within the same
confined axonal regions; nevertheless, frank degeneration of
the distal axon stump was delayed for many hours (Figures
4Dg and 4Dh).
Together, these results indicate that NMN stimulates a late
influx of Ca2+ from the extracellular environment. A more modest
Ca2+ release from intracellular stores also occurs, but this is not
sufficient to trigger fragmentation.
Changes in Mitochondrial Membrane Potential and
Morphology Mark Different Stages of Axonal
Degeneration
Changes in mitochondrial function and structure have been pre-
viously shown to occur after injury (Sievers et al., 2003; Villegas
et al., 2014); however, it is still unclear whether mitochondria are
major players, modest regulators, or simply markers of degener-
ation. As we previously reported early changes in mitochondrial
membrane potential, an index of functionally active mitochon-
dria, in injured neurites of young DRG cultures (Sievers et al.,
2003), we asked whether these changes also occur in our
SCG model of NMN-induced degeneration. Surprisingly, using
the mitochondrial membrane potential indicator tetrame-
thylrhodamine methyl ester perchlorate (TMRM), we found thatthors
Figure 4. The Extracellular Environment Is the Main Source of NMN-Induced Intra-axonal Ca2+ Rise
(A) Schematic representation of the experimental design (not drawn to scale). Wild-type SCG axons were cut and left untreated or treated with FK866
immediately after cut. NMN was added 12 hr after cut and caused degeneration within 3 hr. EGTA, verapamil, and KB-R7943 were added 30 min before NMN
administration. The following concentrations were used: 100 nM FK866, 100 mM NMN, 5 mM EGTA, 10 mM verapamil, 10 mM KB-R7943.
(B) Bright-field images were acquired at the indicated time points after cut. Scale bar represents 35 mm.
(C) Degeneration index was calculated from three fields per sample in three independent experiments (mean ± SEM; n = 9; one-way ANOVA followed by
Bonferroni post hoc test; ****p < 0.0001; **p < 0.01).
(D) Fluorescent and bright-field images of wild-type SCG axons expressing GCaMP5 and TagRFP-mito. Neurites were cut, treated with 100 nM FK866 + 1 mM
NMN (a–d) or with 100 nM FK866 + 1 mM NMN + 5 mM EGTA (e–h) and imaged at the indicated time points. Arrows in (b) and (d) indicate mitochondria co-
localizing with axonal swellings. Localized increases in Ca2+ levels after EGTA treatment were confined in some of the axonal areas where mitochondria were
present (red box and arrowheads in e–h). The enlargement represents the boxed area in panel (e). Scale bar represents 10 mm.
(E) Quantification of Ca2+ peak intensities (see Experimental Procedures). All measurements were normalized to uncut controls (mean ± SEM; n = 6 axons, three
independent experiments; one-way ANOVA followed by Bonferroni post hoc test; *p < 0.05, **p < 0.01).
See also Figures S3, S4, and S5.mitochondrial membrane potential remained stable for at least
4 hr after axotomy, a time point where axons still appear intact
in SCG explant cultures. Similar results were observed after
FK866 treatment and when NMN was re-added to FK866-
treated axons (Figures 5A and 5B). A visible decrease in
TMRM signal only appeared 6 hr after injury, when clear signsCell Repof degeneration were already present. FK866 abolished the
drop in TMRM signal visible at this time point, which was then
re-established by NMN re-addition (Figures S5C and S5D). We
also found that SARM1 deletion delayed the drop in TMRM
signal after injury, which remained stable up to 32 hr after axot-
omy (Figures S5E and S5F).orts 13, 2539–2552, December 22, 2015 ª2015 The Authors 2545
Figure 5. Changes in Mitochondrial Membrane Potential and Morphology Mark Different Stages of Axonal Degeneration
(A) Fluorescent and bright-field (BF) images of wild-type SCG axons, labeled with themitochondrial membrane potential indicator TMRM (50 nM), at the indicated
time points after cut. Where indicated, 100 nM FK866 and 1 mM NMN were added immediately after cut. Scale bar represents 5 mm.
(B) Quantification of relative TMRM intensity (see Experimental Procedures); all measurements were normalized to uncut controls to which an arbitrary value of 1
was assigned (mean ± SD; n = 3, one-way ANOVA followed by Bonferroni post hoc test).
(C) Fluorescent images of wild-type SCG axons, labeled with the mitochondrial marker mitotracker red, at the indicated time points after injury. Where indicated,
100 nM FK866 and 1 mM NMN were added immediately after cut. Scale bar represents 4 mm.
(D) Quantification of mitochondrial length in wild-type SCG axons after cut. The results are expressed as the percentage of mitochondria that fall within the
indicated range of length (total number of mitochondria analyzed per condition: cut untreated, 0 hr n = 359, 4 hr n = 350; Cut + FK866, 0 hr n = 410, 4 hr n = 445;
cut + FK866 + NMN, 0 hr n = 362, 4 hr n = 395; Kolmogorov-Smirnov test).
(E) Fluorescent images of Sarm1/ SCG axons, labeled with the mitochondrial marker mitotracker red, at the indicated time points after injury. Scale bar
represents 4 mm.
(F) Quantification of mitochondrial length in Sarm1/ SCG axons after cut. The results are expressed as detailed above (total number of mitochondria analyzed
per condition: 0 hr n = 418, 48 hr n = 223; Kolmogorov-Smirnov test).
See also Figure S5.Mitochondrial morphological changes have been reported
to be among the earliest detectable alterations during Wallerian
degeneration (Vial, 1958; Webster, 1962). We thus tested
whether NMN accumulation after injury could influence mito-
chondrial morphology. No significant change was observed
among the different treatment groups in the size distribution of
mitochondria immediately after cut (Figures 5C and 5D). We
found a small but significant increase in the number of shorter
mitochondria 4 hr after injury only in the sample treated both
with FK866 and NMN. However, no change was detected in2546 Cell Reports 13, 2539–2552, December 22, 2015 ª2015 The Authe untreated sample, or the sample treated with FK866 alone
(Figures 5C and 5D). Conversely, we observed a dramatic reduc-
tion in mitochondrial length in Sarm1/ axons 48 hr after injury
(Figures 5E and 5F), long before frank fragmentation occurs (Fig-
ures 2A and 2B). Interestingly, we also found a significant differ-
ence (K-S p = 0.0005) in the size distribution of mitochondria
between Sarm1/ and wild-type axons immediately after cut
(compare Figures 5D and 5F), perhaps reflecting a direct influ-
ence of SARM1 on the maintenance of normal mitochondrial
shape.thors
Figure 6. FK866 and SARM1 Deletion Do Not
Prevent Early Changes in Mitochondrial
Motility after Cut
(A) Representative consecutive fluorescent images
of SCG axons labeled with themitochondrial marker
MitoTracker Red. The arrowheads and the arrow
indicate two motile mitochondria relative to a sta-
tionary mitochondria (*).
(B) Quantification of mitochondrial motility in wild-
type SCG axons uncut or cut, treated as indicated
and imaged at the time points shown. Percentage of
motile mitochondria was calculated from two fields
per sample in four different experiments (mean ±
SEM; n = 8; one-way ANOVA followed by Bonferroni
post hoc test; ****p < 0.0001; NS, nonsignificant).
(C) Bright-field images of wild-type SCG axons
showing axonal morphology at the indicated time
points after cut. Scale bar represents 10 mm.
(D) Quantification of mitochondrial motility in
Sarm1/ SCG axons uncut or cut and imaged at
the indicated time points. Percentage of motile
mitochondria was calculated as in (B) (mean ± SEM;
n = 8; one-way ANOVA followed by Bonferroni post
hoc test; **p < 0.01; NS, nonsignificant).
(E) Bright field images of Sarm1/ SCG axons
showing axonal morphology at the indicated time
points after cut. Scale bar represents 10 mm.Thus, in this experimental system, a decrease in mitochondrial
membrane potential marks the late stages of degeneration.
Furthermore, while mitochondrial size is subject to modifications
following an injury, these changes do not appear to correlate with
the extent of degeneration.
FK866 and SARM1 Deletion Do Not Prevent Early
Changes in Mitochondrial Motility after Cut
WLDs was suggested to confer axon protection after injury by
maintaining mitochondrial axonal transport, although this is a
modest and short-lived effect in some studies (Avery et al.,
2012; O’Donnell et al., 2013). Therefore, we next investigated
whether a reduction in mitochondrial motility could underline
NMN-induced axon degeneration.
We tested whether blocking NMN synthesis with FK866 had
an impact on mitochondrial dynamics after injury. To this pur-
pose, we labeled mitochondria with the mitochondrial marker
mitotracker red (Figure 6A). Consistent with previous reports
(Avery et al., 2012; O’Donnell et al., 2013), we found that axot-
omy caused a marked reduction in the percentage of motile
mitochondria 4 hr after cut in SCG explant cultures (Figure 6B;
Movie S5). We also observed a decrease in the number of
motile mitochondria in axons treated with FK866, similar to
that in untreated cut axons (Figure 6B; Movie S5), despite
FK866-treated axons maintaining their integrity during this
time (Figure 6C), and for at least another 30 hr (Di Stefano
et al., 2014). A similar reduction in mitochondrial motility was
also observed in axons treated with both FK866 and NMN (Fig-
ure 6B; Movie S5). Interestingly, FK866-treated axons showed
an almost complete arrest of mitochondrial transport 24 hr after
axotomy, a time point when they still have overtly normal
morphology (Movie S6).Cell RepWe also analyzed mitochondrial transport in Sarm1/ SCG
neurites, where protection against Wallerian degeneration is
even stronger than that achieved with FK866. Remarkably, a
substantial reduction in mitochondrial motility was also detected
as early as 4 hr after injury, when Sarm1/ axons are intact (Fig-
ures 6D and 6E; Movie S7); mitochondrial transport completely
stopped 48 hr after injury (Movie S8), long before axons fragment
(Figures 2A and 2B).
Thus, axon protection by FK866 and SARM1 deletion is not
mediated by an effect on mitochondrial dynamics.
Mitochondrial Depolarization Does Not Alter the Rate of
Wallerian Degeneration
Next, we asked whether direct damage to mitochondria could
affect the rate of Wallerian degeneration. This is possible
because damaged mitochondria could release mediators of
cell and axon death that could cause the axon demise after injury
(Court and Coleman, 2012). Therefore, we treated axons with
the protonophore Carbonyl cyanide m-chlorophenyl hydrazone
(CCCP), which causes an uncoupling of the proton gradient
and disruption of mitochondrial membrane potential (Ly et al.,
2003).
When exposed to 50 mMCCCP, mitochondria in axons imme-
diately lost membrane potential, as shown by a remarkable,
instantaneous decrease in TMRM fluorescent signal (Figure 7A).
Despite this, frank axonal fragmentation only occurred 32–48 hr
after CCCP addition (Figures 7A and 7B). This is a much slower
time course than that of Wallerian degeneration, which in our
experimental system is completed within 8 hr. This remarkable
time difference enabled us to test whether mitochondrial depo-
larization affects the rate of Wallerian degeneration. We added
CCCP to SCG explants immediately prior to axotomy (Figure 7C)orts 13, 2539–2552, December 22, 2015 ª2015 The Authors 2547
Figure 7. Mitochondrial Depolarization Does Not Alter the Rate of Wallerian Degeneration
(A) Uninjured wild-type SCG explants were treated with 50 mM CCCP or vehicle (DMSO); 50 nM TMRM was added to confirm full depolarization of axonal
mitochondria following CCCP addition. Representative bright-field (BF) and representative fluorescent images of wild-type SCG axons were acquired at the
indicated time points after CCCP addition. Scale bars represent 50 and 10 mm.
(B) Degeneration index was calculated from three fields per sample in six independent experiments (mean ±SEM; n = 18; one-way ANOVA followed by Bonferroni
post hoc test; ****p < 0.0001).
(C) Schematic representation of the experimental design (not drawn to scale). Wild-type SCG axons were incubated with 50 nM TMRM to monitor mitochondrial
membrane potential and treated with CCCP (added 10 min before axotomy) or DMSO.
(D) Representative bright-field and representative fluorescent images of transected wild-type SCG axons treated with CCCP or vehicle (DMSO) (a–c) and with
100 nM FK866 (b) or with 100 nM FK866 + 1 mM NMN (c). The dramatic loss of TMRM signal following CCCP addition confirmed full depolarization of axonal
mitochondria. Scale bars represent 50 and 10 mm.
(E–G) Degeneration index was calculated from three fields per sample in three independent experiments (mean ± SEM; n = 9; one-way ANOVA followed by
Bonferroni post hoc test).
See also Figure S6.and then followed the time course of axon degeneration.
Despite the much earlier, almost instantaneous loss of TMRM
signal, cut axons treated with CCCP underwent Wallerian
degeneration at the same rate as cut, vehicle-treated axons
(Figures 7Da and 7E). Furthermore, CCCP treatment did not
affect axon protection conferred by FK866 or reversion by
NMN administration after axotomy (Figures 7Db, 7Dc, 7F, and2548 Cell Reports 13, 2539–2552, December 22, 2015 ª2015 The Au7G). Similarly, the rate of axon degeneration in transected
Sarm1/ axons treated with CCCP did not differ from that of
the untreated axons, despite the rapid depolarization of
Sarm1/ mitochondria upon CCCP addiction, as expected
(Figures S6A and S6B).
Together, these results dissociate the loss of mitochondrial
function from the onset of Wallerian degeneration.thors
DISCUSSION
Our proposed model of Wallerian degeneration predicts that
axonal integrity is lost as a consequence of the accumulation
of the pro-degenerative molecule NMN (Di Stefano et al.,
2014), whose levels in axons are normally limited by the NAD-
biosynthetic enzyme NMNAT2 (Gilley and Coleman, 2010).
Here, using pharmacological and genetic experimental ap-
proaches in in vitro mammalian primary neurons and an in vivo
vertebrate model organism, we show that NMN initiates a
Ca2+-mediated execution program of axon degeneration after
injury, which requires the presence of the recently identified
pro-axon death protein SARM1. Furthermore, inhibition of
NMN synthesis and SARM1 deletion both fail to prevent early
alterations in mitochondrial motility after cut and disrupting mito-
chondrial membrane potential does not affect the rate of injury-
induced axon degeneration; thus, a change in mitochondrial
homeostasis appears to be a marker of Wallerian degeneration
rather than a causative event.
Although our NMN-induced axon degeneration model is sup-
ported by pharmacological and genetic studies in vitro and
in vivo (see Figures 1 and 3 and Di Stefano et al., 2014),
some recent studies find instead a beneficial effect of NMN, ex-
plained by its intra-axonal conversion to NAD (Wang et al.,
2015). The difference in our experimental settings (mouse
intact explants instead of rat dissociated neurons) precludes
a direct comparison. However, in our hands, NMN shows a
rapid pro-degenerative effect when added up to 12 hr (SCG ex-
plants) or 24 hr (DRG explants) post-axotomy (see Figure 4,
Figure S4, and Di Stefano et al., 2014); at these time points,
NMN conversion to NAD is prevented by the complete degra-
dation of NMNAT2, whose activity could remain in the experi-
ments performed by (Wang et al., 2015). Careful comparison
studies will need to address these discrepancies to reconcile
these apparent contradictions.
Intra-axonal Ca2+ increase after axotomy follows a biphasic
pattern, showing a first rise soon after and near the site of injury
followed by second, delayed one along the whole axon length;
however its temporal relationship with axonal fragmentation is
still debated (Adalbert et al., 2012; Avery et al., 2012; Gerdts
et al., 2011; Villegas et al., 2014; Yang et al., 2013). Our finding
that NMN induces a late intra-axonal Ca2+ increase after injury,
which is rapidly followed by axonal degeneration, are consistent
with a model in which the late Ca2+ rise is the central and caus-
ative event marking the execution phase of degeneration on
which several other mediators may converge.
Consistent with a recent report that SARM1 is required for
degeneration downstream of NMNAT2 loss (Gilley et al., 2015),
our data suggest that Ca2+ lies downstream of both NMN and
SARM1 in amain, unique axon death pathway (Figure S6C; Con-
forti et al., 2014). A recent study proposed that SARM1 acts
downstream of intra-axonal Ca2+ increase (Summers et al.,
2014). The early Ca2+ rise has been suggested as a causative
step in Wallerian degeneration (Avery et al., 2012). Our data,
however, indicate that the early Ca2+ increase in the proximity
of the cut site and its associated acute degeneration occur indis-
tinguishably in wild-type rapidly degenerating axons as well in
Sarm1/, NMN deamidase and FK866-treated axons, all condi-Cell Reptions where Wallerian degeneration is dramatically delayed.
Similarly, WLDs does not prevent the early rise of Ca2+ near the
cut site (Adalbert et al., 2012). Furthermore, Ca2+ blockers delay
degeneration induced by NMN in axons injured as long as 12 hr
earlier but maintained intact by FK866. Crucially, WLDs-sensitive
Wallerian degeneration can be induced without injury in vitro or
in vivo by NMNAT2 selective depletion (Gilley and Coleman,
2010; Hicks et al., 2012) and does not require an influx of Ca2+
from the cut site to initiate it. All these observations dissociate
initial Ca2+ influx from degeneration.
Two ways of preventing Ca2+ influx from the extracellular
environment confer strong protection from NMN-induced axon
degeneration: (1) sequestering extracellular Ca2+ with EGTA,
and (2) blocking Ca2+ influx via Ca2+ channels. While strongly
implicating extracellular Ca2+ in the late execution stages ofWal-
lerian degeneration, these observations suggest that the Ca2+
sensitive step could be at a point wheremorphologically protect-
ing axons may not restore their function. Therefore, upstream
mediators of the axon death pathway may prove therapeutically
more useful targets.
Extracellular Ca2+ influx may be due to a dysregulation of
Ca2+ channels following a depolarization of the axonal mem-
brane, which itself could be a consequence of energy depletion
(Mishra et al., 2013; Wang et al., 2005). This could be triggered
by activation of a MAPK signaling pathway by SARM1 (Yang
et al., 2015) or even by a downstream effect on NAD levels
(Gerdts et al., 2015). Consistent with previous reports (Barrien-
tos et al., 2011; Villegas et al., 2014), our data also indicate a
small contribution of intracellular organelles to the total intra-
axonal Ca2+ rise after injury, noticeable following EGTA treat-
ment (Figures 4D and 4E). Despite being insufficient to trigger
fragmentation on its own in the rapid timescale of Wallerian
degeneration, this could nevertheless contribute to the degen-
eration process. Our observation that mitochondria localize at
the sites of Ca2+ accumulation suggests they could be one of
the sources of this weaker Ca2+ increase. Consistently, we
found a protective effect when interfering with mPTP opening
(Figures S3C and S3D), even if more modest to what previously
reported ex vivo (Barrientos et al., 2011), where Schwann cells
and, more specifically, an effect of the pharmacological treat-
ments on Schwann cell mitochondria, could have a stronger in-
fluence on axonal survival.
Whether mitochondria play a central role inWallerian degener-
ation, and whether reported changes in mitochondrial shape,
dynamics, and membrane potential (Avery et al., 2012; Sievers
et al., 2003; Villegas et al., 2014) are a cause or consequence
of degeneration or are general markers of compromised axons
remain unclear. In our model of NMN-induced axon degenera-
tion, we find that mitochondrial membrane potential drops
after cut, but only when morphological damages to axons are
already present, and may even be a consequence of Ca2+ influx.
Crucially, disrupting mitochondrial membrane potential before
injury does not alter the rate of degeneration or the effect of
FK866 and SARM1 deletion. Consistent with our data, Wallerian
degeneration occurs also in axons devoid of mitochondria and
WLDs protection is independent of axonal mitochondria (Kitay
et al., 2013; Rawson et al., 2014). The depletion of other axonal
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homeostasis. For instance, SCG10, which is involved in the regu-
lation of mitochondrial dynamics, is also rapidly lost after injury
and its overexpression confers a modest protective phenotype
(Shin et al., 2012), raising the possibility that mitochondrial
changesmay follow the depletion of such a regulator. In addition,
mitochondrial arrest could also be a response to local Ca2+
changes (Wang and Schwarz, 2009). Mitochondria depend on
the integrity of a nuclear-mitochondrial communication pathway
regulated by NAD metabolism (Fang et al., 2014), and could be
affected when this control is lost as consequence of the injury.
Intriguingly, axonal mitochondria appear shorter and more
static in the absence of SARM1. While supporting that Wallerian
degeneration is independent of mitochondrial shape and
motility, these observations raise a series of questions on the
role of SARM1 in mitochondria. Indeed, SARM1 contains an
N-terminal mitochondrial localization signal and is, at least in
part, associated with mitochondria (Osterloh et al., 2012).
SARM1 mitochondrial localization may be dispensable for the
execution of Wallerian degeneration; however, it is required for
viral-induced cell death (Mukherjee et al., 2013). The relevance
of mitochondrial homeostasis in SARM1 biological function
therefore needs to be further explored.
In our hands treatment of axons with CCCP to induce mito-
chondrial depolarization does not affect the rate of Wallerian
degeneration, but it does initiate a slower axonal degeneration
process in intact axons. A previous study showed that CCCP
toxicity in uninjured axons was insensitive to WLDs (Ikegami
and Koike, 2003), which may appear in contrast to our result.
However, we used CCCP at a lower concentration and, most
importantly, in the context of axotomy where CCCP action
could differ. Intriguingly, other reports show that mitochondrial
dysfunctions activate a pathway of degeneration sensitive to
regulators of Wallerian degeneration (Press and Milbrandt,
2008; Summers et al., 2014). This mechanism could be different
from the axon degeneration induced by depletion of axonal mito-
chondria (Fang et al., 2012; Rawson et al., 2014), which in
contrast is insensitive to NMNAT/WLDs pathway (Fang et al.,
2012). Furthermore, in C. elegans mitochondrial and transport
defects leading to axon degeneration are observed as a con-
sequence of a-tubulin acetyltransferase gene mec-17 loss (Neu-
mann and Hilliard, 2014). Explaining the mechanistic links be-
tween mitochondrial dysfunction-induced axon degeneration
andWallerian degeneration will be important in view of the caus-
ative role of mitochondrial dysfunction in a variety of neurode-
generative disorders characterized by axonal degeneration
(Conforti et al., 2014).
In summary, our data identify crucial steps of an axon death
pathway initiated by NMN accumulation. We show that NMN
requires SARM1 to activate a destruction process where extra-
cellular Ca2+ influx is the main executor (Figure S6C). We reveal
an additional, minor contribution of mitochondrial Ca2+ release
but our data do not support a central role for mitochondria
in NMN-induced axon degeneration. Because Ca2+ appears to
be temporally distant from the point of NMN accumulation, leav-
ing time for signaling events, it is now important to clarify what
are these signals and how NMN interacts with SARM1. These
studies should help identifying effective targets to delay axon
degeneration in injury and disease.2550 Cell Reports 13, 2539–2552, December 22, 2015 ª2015 The AuEXPERIMENTAL PROCEDURES
All studies conformed to the institution’s ethical requirements in accordance
with the 1986 Animals (Scientific Procedures) Act.
Explant and Dissociated Cell Cultures
C57BL/6 or CD1 (referred to as wild-type, Charles River, UK) and Sarm1/
(kindly provided by Dr. Michael Coleman, the Babraham Institute) mouse
SCG explants, were dissected from P0-2 mouse pups and DRG explants
were dissected from E16 mouse embryos. Explants were cultured for
6–7 days and then axotomized as previously described (Di Stefano et al.,
2014) and as detailed in the Supplemental Experimental Procedures.
Wild-type and Sarm1/ SCG dissociated neurons were obtained
as described (Di Stefano et al., 2014) and as detailed in Supplemental
Experimental Procedures. Neurites were allowed to extend for 3 days in
culture before microinjection and were axotomised the following day using
a scalpel. We refer to time 0 as the first time point acquired immediately
after cut.
In our experimental system (Di Stefano et al., 2014), neurites originating from
wild-type SCG explants degenerate within 8 hr after cut. For the purpose of
comparison, no morphological changes occur in wild-types within the first
4 hr after cut; clear morphological damages and frank fragmentation occur
at 6–8 hr after cut. Neurites originating from dissociated cells degenerate
within 3 hr after cut; this difference could be due to the different time in
culture (Buckmaster et al., 1995).
Microinjection
Dissociated cells were microinjected as described in (Di Stefano et al., 2014)
and in the Supplemental Experimental Procedures.
Ca2+ Imaging and Quantification
Wild-type and Sarm1/ dissociated SCG neurons were cut and then imaged
in a controlled environment (37C and 5% CO2). Treatments were applied
30 min before cut or immediately after cut and time-lapse fluorescent images
and bright-field images were acquired analyzed and quantified as detailed in
the Supplemental Experimental Procedures.
Ca2+ Imaging and Quantification in Zebrafish Larvae
Zebrafish larvae were grown, transfected, axotomised, and imaged as
described (Di Stefano et al., 2014) and as detailed in the Supplemental Exper-
imental Procedures.
SCG and DRG Explant Treatment and Acquisition of Bright-Field
Images
Wild-type SCG neurites were cut and drugs were administered as described in
(Di Stefano et al., 2014) and in Supplementary Methods. Bright field images
were acquired and analyzed as detailed in the Supplemental Experimental
Procedures.
Mitochondrial Motility Imaging and Quantification
Wild-type and Sarm1/ SCG explants were pre-incubated with 100nM Mito-
tracker red CMXRos (Invitrogen) for 15 min at 37C before axotomy. Drug
treatment and image acquisition is detailed in the Supplemental Experimental
Procedures.
Quantification of mitochondrial motility was performed using the ImageJ
plugin Difference tracker (Andrews et al., 2010). Differences in contrast
between each movie were minimized by applying automated contrast normal-
ization to all images using ImageJ.
Mitochondrial Membrane Potential and Length Quantification
For mitochondrial membrane potential, wild-type and Sarm1/ SCG
neurons were incubated with the cell-permeant dye TMRM (VWR Inter-
national) for 30 min at 37C before axotomy and imaging. When
used, 100 nM FK866 and 1mM NMN were administered immediately
after axotomy. For mitochondrial length, wild-type and Sarm1/ SCG
explants were incubated with 100 nM Mitotracker red CMXRos (Invi-
trogen) for 15 min at 37C before cutting. Drug treatment, imagethors
acquisition and image analysis are detailed in the Supplemental Experi-
mental Procedures.
CCCP Treatment
Uncut and cut wild-type or cut Sarm1/ SCG neurons were treated with
50 mM CCCP or vehicle (DMSO) just prior to imaging. To check that CCCP
treatment was triggering full depolarization of axonal mitochondria neurons
were incubated for 30 min at 37C with TMRM.
Statistical Analysis
Data are expressed as mean ± SEM or SD. Statistical analysis was performed
using ANOVA, Kolmogorov-Smirnov test, or Student’s t test with p values less
than 0.05 being considered significant for any set of data.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and eight movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.11.032.
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